TBX-1400 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 65 | 原発性免疫不全症候群 | 1 |
65. 原発性免疫不全症候群
臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02860559 (ClinicalTrials.gov) | August 2021 | 26/7/2016 | Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency | Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency | Severe Combined Immunodeficiency | Biological: TBX-1400 | Taiga Biotechnologies, Inc. | NULL | Not yet recruiting | 1 Month | 4 Years | All | 8 | Phase 1 | Israel |